Efficacy and safety of abediterol (LAS100977) in patients with COPD: Phase II, randomised, crossover study

J. Beier, H. Pujol, B. Seoane, E. Jimenez, C. Astbury, S. Ruiz, G. de Miquel (Wiesbaden, Germany; Barcelona, Spain)

Source: Annual Congress 2013 –New bronchodilators for COPD management
Session: New bronchodilators for COPD management
Session type: Oral Presentation
Number: 183
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
J. Beier, H. Pujol, B. Seoane, E. Jimenez, C. Astbury, S. Ruiz, G. de Miquel (Wiesbaden, Germany; Barcelona, Spain). Efficacy and safety of abediterol (LAS100977) in patients with COPD: Phase II, randomised, crossover study. Eur Respir J 2013; 42: Suppl. 57, 183

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Efficacy and safety of abediterol (LAS100977) in stable asthma: Phase II, randomized, crossover study
Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD
Year: 2013

Abediterol in stable asthma:efficacy, safety and tolerability results from a Phase II, randomised, crossover study
Source: International Congress 2014 – Asthma and COPD management
Year: 2014

Lung function with aclidinium/formoterol fixed-dose combination: Pooled analysis of two phase III studies in COPD
Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD
Year: 2015


A randomised double-blind placebo-controlled trial of the effect of inhaled heparin on lung function, hyperinflation and exercise capacity in patients with COPD
Source: International Congress 2016 – Novel insights into the treatment of COPD
Year: 2016

A phase II, randomised, placebo controlled trial of 12 weeks treatment with an oral p38 inhibitor in patients with COPD on a background of ICS/LABA
Source: Annual Congress 2013 –New bronchodilators for COPD management
Year: 2013

Roflumilast for stable COPD: Meta-analysis of randomized controlled trials
Source: International Congress 2014 – Clinical presentations
Year: 2014


Efficacy and safety of erdosteine in COPD: Results of a 12-month prospective, multinational study
Source: International Congress 2015 – New data on established treatments for COPD
Year: 2015


Efficacy and safety of aclidinium bromide vs placebo and tiotropium in COPD: A phase IIIb study
Source: Annual Congress 2013 –New bronchodilators for COPD management
Year: 2013

Phase III trial of tiotropium as add-on therapy to low-dose inhaled corticosteroids for patients with symptomatic mild persistent asthma: Design and planned analyses
Source: Annual Congress 2013 –Asthma drugs: new findings
Year: 2013


Evaluation of ICS/LABA combination therapy on respiratory function in patients with asthma: Open-label, randomized, cross-over trial.
Source: International Congress 2018 – New developments in the treatment of asthma
Year: 2018


Real-life study on the aPpropriaTeness of treatment in moderate COPD patients (OPTIMO)
Source: Annual Congress 2013 –COPD drugs: new findings
Year: 2013


The TRIFLOW study; A randomised, cross-over study evaluating the effects of inhaled beclometasone/formoterol/glycopyrronium (BDP/F/G) on hyperinflation in COPD
Source: Virtual Congress 2020 – Clinical studies of COPD: combination inhalers and much more
Year: 2020


Safety and effectiveness of indacaterol in Korean COPD patients: A post-marketing surveillance (PMS) study
Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD
Year: 2015

RCT Abstract - Randomized, double-blind, placebo-controlled, phase III clinical trial with MV130, a sublingual bacterial immunotherapy to prevent COPD exacerbations
Source: Virtual Congress 2021 – ALERT: COPD
Year: 2021



INSTEAD: Randomized switch trial of indacaterol and salmeterol/fluticasone combination (SFC) in moderate COPD: Symptoms results
Source: International Congress 2015 – New data on established treatments for asthma and COPD
Year: 2015

LATE-BREAKING ABSTRACT: A Phase 1b study of PUR0200, a novel tiotropium formulation, in COPD patients
Source: International Congress 2015 – Emerging strategies for airway disease treatments
Year: 2015

Reslizumab (RES) in patients (pts) with inadequately controlled asthma and elevated blood eosinophils (EOS): Analysis of two phase 3, placebo-controlled trials
Source: International Congress 2016 – Asthma: from basic mechanisms to novel therapeutic perspectives
Year: 2016



RCT Abstract - Using a smartphone application in COPD patients to increase physical activity following pulmonary rehabilitation. Results of the AMOPUR Study, a multicenter, randomized, controlled study
Source: Virtual Congress 2021 – A multidisciplinary approach to the management of chronic respiratory diseases
Year: 2021



Budesonide/formoterol vs formoterol, both via Turbuhaler®, in patients with moderate to severe COPD: Phase III study results
Source: Annual Congress 2012 - COPD treatments: efficacy and safety
Year: 2012


“Stepping down” in mild-to-moderate asthmatic children being well controlled while receiving low doses of inhaled corticosteroids (ICS): Daily vs. cyclical ICS administration (prospective, randomized, multicentre, open-label trial)
Source: Annual Congress 2013 –Asthma treatment and management in children
Year: 2013